APO Research
Talk to an analyst

APO RESEARCH · REPORT

Drugs for Vancomycin-Resistant Enterococcus Faecium

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Drugs for Vancomycin-Resistant Enterococcus Faecium Market Outlook and Growth Opportunities 2026

19 December 2025197 pages

Choose your research edition.

Industry ResearchDrugs for Vancomycin-Resistant Enterococcus Faecium Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Drugs for Vancomycin-Resistant Enterococcus Faecium Industry Growth and Trends Forecast to 2032100 pages · $3,450 USDMarket StructureGlobal Drugs for Vancomycin-Resistant Enterococcus Faecium Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Drugs for Vancomycin-Resistant Enterococcus Faecium Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Drugs for Vancomycin-Resistant Enterococcus Faecium Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Drugs for Vancomycin-Resistant Enterococcus Faecium market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Drugs for Vancomycin-Resistant Enterococcus Faecium is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Drugs for Vancomycin-Resistant Enterococcus Faecium is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Drugs for Vancomycin-Resistant Enterococcus Faecium is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Drugs for Vancomycin-Resistant Enterococcus Faecium market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Drugs for Vancomycin-Resistant Enterococcus Faecium market include Microbiotix, MGB Biopharma Limited, Lytix Biopharma, LegoChem Biosciences, Helix BioMedix, Enanta Pharmaceuticals, Cellceutix Corporation, Aphios Corporation and Alvogen, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Drugs for Vancomycin-Resistant Enterococcus Faecium market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Drugs for Vancomycin-Resistant Enterococcus Faecium and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Drugs for Vancomycin-Resistant Enterococcus Faecium revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Drugs for Vancomycin-Resistant Enterococcus Faecium market.

Drugs for Vancomycin-Resistant Enterococcus Faecium Segment by Company

Microbiotix

MGB Biopharma Limited

Lytix Biopharma

LegoChem Biosciences

Helix BioMedix

Enanta Pharmaceuticals

Cellceutix Corporation

Aphios Corporation

Alvogen

Alchemia Limited

Drugs for Vancomycin-Resistant Enterococcus Faecium Segment by Type

Ampicillin

Daptomycin

Quinupristin/dalfopristin

Linezolid

Chloramphenicol

Others

Drugs for Vancomycin-Resistant Enterococcus Faecium Segment by Application

Hospital

Clinic

Others

Drugs for Vancomycin-Resistant Enterococcus Faecium Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global Drugs for Vancomycin-Resistant Enterococcus Faecium status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Drugs for Vancomycin-Resistant Enterococcus Faecium key companies, revenue, market share, and recent developments.

3. To split the Drugs for Vancomycin-Resistant Enterococcus Faecium breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Drugs for Vancomycin-Resistant Enterococcus Faecium market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Drugs for Vancomycin-Resistant Enterococcus Faecium significant trends, drivers, influence factors in global and regions.

6. To analyze Drugs for Vancomycin-Resistant Enterococcus Faecium competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Drugs for Vancomycin-Resistant Enterococcus Faecium market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Drugs for Vancomycin-Resistant Enterococcus Faecium and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Drugs for Vancomycin-Resistant Enterococcus Faecium.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Drugs for Vancomycin-Resistant Enterococcus Faecium industry.

Chapter 3: Detailed analysis of Drugs for Vancomycin-Resistant Enterococcus Faecium company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Drugs for Vancomycin-Resistant Enterococcus Faecium in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Drugs for Vancomycin-Resistant Enterococcus Faecium in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Drugs for Vancomycin-Resistant Enterococcus Faecium Industry Trends Table 2. Drugs for Vancomycin-Resistant Enterococcus Faecium Industry Drivers Table 3. Drugs for Vancomycin-Resistant Enterococcus Faecium Industry Opportunities and Challenges Table 4. Drugs for Vancomycin-Resistant Enterococcus Faecium Industry Restraints Table 5. Global Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue Share by Company (2021-2026) Table 7. Global Drugs for Vancomycin-Resistant Enterococcus Faecium Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Drugs for Vancomycin-Resistant Enterococcus Faecium Key Company Manufacturing Base & Headquarters Table 9. Global Drugs for Vancomycin-Resistant Enterococcus Faecium Company, Product Type & Application Table 10. Global Drugs for Vancomycin-Resistant Enterococcus Faecium Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Drugs for Vancomycin-Resistant Enterococcus Faecium by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Ampicillin Table 15. Significant Companies of Daptomycin Table 16. Significant Companies of Quinupristin/dalfopristin Table 17. Significant Companies of Linezolid Table 18. Significant Companies of Chloramphenicol Table 19. Significant Companies of Others Table 20. Global Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 21. Global Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value by Type (2021-2026) & (US$ Million) Table 22. Global Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value by Type (2027-2032) & (US$ Million) Table 23. Global Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Type (2021-2026) Table 24. Global Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Type (2027-2032) Table 25. Significant Companies of Hospital Table 26. Significant Companies of Clinic Table 27. Significant Companies of Others Table 28. Global Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 29. Global Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value by Application (2021-2026) & (US$ Million) Table 30. Global Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value by Application (2027-2032) & (US$ Million) Table 31. Global Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Application (2021-2026) Table 32. Global Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Application (2027-2032) Table 33. Global Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 34. Global Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value by Region (2021-2026) & (US$ Million) Table 35. Global Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Region (2021-2026) Table 36. Global Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value by Region (2027-2032) & (US$ Million) Table 37. Global Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Region (2027-2032) Table 38. Global Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value by Country (2021-2026) & (US$ Million) Table 40. Global Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Market Share by Country (2021-2026) Table 41. Global Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value by Country (2027-2032) & (US$ Million) Table 42. Global Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Market Share by Country (2027-2032) Table 43. Microbiotix Company Information Table 44. Microbiotix Business Overview Table 45. Microbiotix Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue (US$ Million) and Gross Margin (2021-2026) Table 46. Microbiotix Drugs for Vancomycin-Resistant Enterococcus Faecium Product Portfolio Table 47. Microbiotix Recent Development Table 48. MGB Biopharma Limited Company Information Table 49. MGB Biopharma Limited Business Overview Table 50. MGB Biopharma Limited Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue (US$ Million) and Gross Margin (2021-2026) Table 51. MGB Biopharma Limited Drugs for Vancomycin-Resistant Enterococcus Faecium Product Portfolio Table 52. MGB Biopharma Limited Recent Development Table 53. Lytix Biopharma Company Information Table 54. Lytix Biopharma Business Overview Table 55. Lytix Biopharma Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue (US$ Million) and Gross Margin (2021-2026) Table 56. Lytix Biopharma Drugs for Vancomycin-Resistant Enterococcus Faecium Product Portfolio Table 57. Lytix Biopharma Recent Development Table 58. LegoChem Biosciences Company Information Table 59. LegoChem Biosciences Business Overview Table 60. LegoChem Biosciences Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue (US$ Million) and Gross Margin (2021-2026) Table 61. LegoChem Biosciences Drugs for Vancomycin-Resistant Enterococcus Faecium Product Portfolio Table 62. LegoChem Biosciences Recent Development Table 63. Helix BioMedix Company Information Table 64. Helix BioMedix Business Overview Table 65. Helix BioMedix Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue (US$ Million) and Gross Margin (2021-2026) Table 66. Helix BioMedix Drugs for Vancomycin-Resistant Enterococcus Faecium Product Portfolio Table 67. Helix BioMedix Recent Development Table 68. Enanta Pharmaceuticals Company Information Table 69. Enanta Pharmaceuticals Business Overview Table 70. Enanta Pharmaceuticals Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue (US$ Million) and Gross Margin (2021-2026) Table 71. Enanta Pharmaceuticals Drugs for Vancomycin-Resistant Enterococcus Faecium Product Portfolio Table 72. Enanta Pharmaceuticals Recent Development Table 73. Cellceutix Corporation Company Information Table 74. Cellceutix Corporation Business Overview Table 75. Cellceutix Corporation Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue (US$ Million) and Gross Margin (2021-2026) Table 76. Cellceutix Corporation Drugs for Vancomycin-Resistant Enterococcus Faecium Product Portfolio Table 77. Cellceutix Corporation Recent Development Table 78. Aphios Corporation Company Information Table 79. Aphios Corporation Business Overview Table 80. Aphios Corporation Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue (US$ Million) and Gross Margin (2021-2026) Table 81. Aphios Corporation Drugs for Vancomycin-Resistant Enterococcus Faecium Product Portfolio Table 82. Aphios Corporation Recent Development Table 83. Alvogen Company Information Table 84. Alvogen Business Overview Table 85. Alvogen Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue (US$ Million) and Gross Margin (2021-2026) Table 86. Alvogen Drugs for Vancomycin-Resistant Enterococcus Faecium Product Portfolio Table 87. Alvogen Recent Development Table 88. Alchemia Limited Company Information Table 89. Alchemia Limited Business Overview Table 90. Alchemia Limited Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue (US$ Million) and Gross Margin (2021-2026) Table 91. Alchemia Limited Drugs for Vancomycin-Resistant Enterococcus Faecium Product Portfolio Table 92. Alchemia Limited Recent Development Table 93. Research Programs/Design for This Report Table 94. Authors List of This Report Table 95. Secondary Sources Table 96. Primary Sources List of Figures Figure 1. Drugs for Vancomycin-Resistant Enterococcus Faecium Product Image Figure 2. Global Drugs for Vancomycin-Resistant Enterococcus Faecium Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Drugs for Vancomycin-Resistant Enterococcus Faecium Market Size (2021-2032) & (US$ Million) Figure 4. Global Drugs for Vancomycin-Resistant Enterococcus Faecium Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Ampicillin Image Figure 8. Daptomycin Image Figure 9. Quinupristin/dalfopristin Image Figure 10. Linezolid Image Figure 11. Chloramphenicol Image Figure 12. Others Image Figure 13. Global Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 14. Global Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share 2021 VS 2025 VS 2032 Figure 15. Global Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Type (2021-2032) Figure 16. Hospital Image Figure 17. Clinic Image Figure 18. Others Image Figure 19. Global Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share 2021 VS 2025 VS 2032 Figure 21. Global Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Application (2021-2032) Figure 22. Global Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 23. Global Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 24. North America Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value (2021-2032) & (US$ Million) Figure 25. North America Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Europe Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value (2021-2032) & (US$ Million) Figure 27. Europe Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Asia-Pacific Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value (2021-2032) & (US$ Million) Figure 29. Asia-Pacific Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Country (%), 2025 VS 2032 Figure 30. South America Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value (2021-2032) & (US$ Million) Figure 31. South America Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Middle East & Africa Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value (2021-2032) & (US$ Million) Figure 33. Middle East & Africa Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Country (%), 2025 VS 2032 Figure 34. USA Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. USA Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. USA Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Canada Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Canada Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Canada Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Mexico Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Mexico Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Mexico Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Germany Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Germany Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Germany Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. France Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. France Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. France Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. U.K. Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. U.K. Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. U.K. Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Italy Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Italy Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Italy Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Spain Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Spain Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Spain Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Russia Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Russia Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Russia Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Netherlands Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Netherlands Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Netherlands Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Nordic Countries Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Nordic Countries Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Nordic Countries Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. China Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. China Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. China Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Japan Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Japan Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Japan Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. South Korea Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. South Korea Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. South Korea Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. India Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. India Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. India Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Australia Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Australia Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Australia Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Southeast Asia Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Southeast Asia Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Southeast Asia Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Brazil Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Brazil Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Brazil Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Argentina Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Argentina Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Argentina Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Chile Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Chile Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Chile Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Colombia Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Colombia Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Colombia Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Peru Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Peru Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Peru Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Saudi Arabia Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Saudi Arabia Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Saudi Arabia Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Israel Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Israel Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Israel Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. UAE Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. UAE Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. UAE Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Turkey Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Turkey Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Turkey Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Iran Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Iran Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Iran Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Egypt Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Egypt Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Egypt Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Years Considered Figure 119. Research Process Figure 120. Key Executives Interviewed

Scope & coverage.

Types
  • Ampicillin
  • Daptomycin
  • Quinupristin/dalfopristin
  • Linezolid
  • Chloramphenicol
  • Others
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Microbiotix
  • MGB Biopharma Limited
  • Lytix Biopharma
  • LegoChem Biosciences
  • Helix BioMedix
  • Enanta Pharmaceuticals
  • Cellceutix Corporation
  • Aphios Corporation
  • Alvogen
  • Alchemia Limited

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Drugs for Vancomycin-Resistant Enterococcus Faecium Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Drugs for Vancomycin-Resistant Enterococcus Faecium Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Drugs for Vancomycin-Resistant Enterococcus Faecium Market Dynamics
  1. 2.1 Drugs for Vancomycin-Resistant Enterococcus Faecium Industry Trends
  2. 2.2 Drugs for Vancomycin-Resistant Enterococcus Faecium Industry Drivers
  3. 2.3 Drugs for Vancomycin-Resistant Enterococcus Faecium Industry Opportunities and Challenges
  4. 2.4 Drugs for Vancomycin-Resistant Enterococcus Faecium Industry Restraints
3 Drugs for Vancomycin-Resistant Enterococcus Faecium Market by Company
  1. 3.1 Global Drugs for Vancomycin-Resistant Enterococcus Faecium Company Revenue Ranking in 2025
  2. 3.2 Global Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue by Company (2021-2026)
  3. 3.3 Global Drugs for Vancomycin-Resistant Enterococcus Faecium Company Ranking (2024-2026)
  4. 3.4 Global Drugs for Vancomycin-Resistant Enterococcus Faecium Company Manufacturing Base and Headquarters
  5. 3.5 Global Drugs for Vancomycin-Resistant Enterococcus Faecium Company Product Type and Application
  6. 3.6 Global Drugs for Vancomycin-Resistant Enterococcus Faecium Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Drugs for Vancomycin-Resistant Enterococcus Faecium Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Drugs for Vancomycin-Resistant Enterococcus Faecium Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Drugs for Vancomycin-Resistant Enterococcus Faecium Market by Type
  1. 4.1 Drugs for Vancomycin-Resistant Enterococcus Faecium Type Introduction
  2. 4.1.1 Ampicillin
  3. 4.1.2 Daptomycin
  4. 4.1.3 Quinupristin/dalfopristin
  5. 4.1.4 Linezolid
  6. 4.1.5 Chloramphenicol
  7. 4.1.6 Others
  8. 4.2 Global Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value by Type
  9. 4.2.1 Global Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.2.2 Global Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value by Type (2021-2032)
  11. 4.2.3 Global Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Type (2021-2032)
5 Drugs for Vancomycin-Resistant Enterococcus Faecium Market by Application
  1. 5.1 Drugs for Vancomycin-Resistant Enterococcus Faecium Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Others
  5. 5.2 Global Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value by Application
  6. 5.2.1 Global Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value by Application (2021-2032)
  8. 5.2.3 Global Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Application (2021-2032)
6 Drugs for Vancomycin-Resistant Enterococcus Faecium Regional Value Analysis
  1. 6.1 Global Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value by Region (2021-2032)
  3. 6.2.1 Global Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value by Region: 2021-2026
  4. 6.2.2 Global Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value (2021-2032)
  7. 6.3.2 North America Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value (2021-2032)
  10. 6.4.2 Europe Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value (2021-2032)
  16. 6.6.2 South America Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Country, 2025 VS 2032
7 Drugs for Vancomycin-Resistant Enterococcus Faecium Country-level Value Analysis
  1. 7.1 Global Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value by Country (2021-2032)
  3. 7.2.1 Global Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value by Country (2021-2026)
  4. 7.2.2 Global Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Drugs for Vancomycin-Resistant Enterococcus Faecium Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Microbiotix
  2. 8.1.1 Microbiotix Company Information
  3. 8.1.2 Microbiotix Business Overview
  4. 8.1.3 Microbiotix Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Microbiotix Drugs for Vancomycin-Resistant Enterococcus Faecium Product Portfolio
  6. 8.1.5 Microbiotix Recent Developments
  7. 8.2 MGB Biopharma Limited
  8. 8.2.1 MGB Biopharma Limited Company Information
  9. 8.2.2 MGB Biopharma Limited Business Overview
  10. 8.2.3 MGB Biopharma Limited Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue and Gross Margin (2021-2026)
  11. 8.2.4 MGB Biopharma Limited Drugs for Vancomycin-Resistant Enterococcus Faecium Product Portfolio
  12. 8.2.5 MGB Biopharma Limited Recent Developments
  13. 8.3 Lytix Biopharma
  14. 8.3.1 Lytix Biopharma Company Information
  15. 8.3.2 Lytix Biopharma Business Overview
  16. 8.3.3 Lytix Biopharma Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Lytix Biopharma Drugs for Vancomycin-Resistant Enterococcus Faecium Product Portfolio
  18. 8.3.5 Lytix Biopharma Recent Developments
  19. 8.4 LegoChem Biosciences
  20. 8.4.1 LegoChem Biosciences Company Information
  21. 8.4.2 LegoChem Biosciences Business Overview
  22. 8.4.3 LegoChem Biosciences Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue and Gross Margin (2021-2026)
  23. 8.4.4 LegoChem Biosciences Drugs for Vancomycin-Resistant Enterococcus Faecium Product Portfolio
  24. 8.4.5 LegoChem Biosciences Recent Developments
  25. 8.5 Helix BioMedix
  26. 8.5.1 Helix BioMedix Company Information
  27. 8.5.2 Helix BioMedix Business Overview
  28. 8.5.3 Helix BioMedix Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Helix BioMedix Drugs for Vancomycin-Resistant Enterococcus Faecium Product Portfolio
  30. 8.5.5 Helix BioMedix Recent Developments
  31. 8.6 Enanta Pharmaceuticals
  32. 8.6.1 Enanta Pharmaceuticals Company Information
  33. 8.6.2 Enanta Pharmaceuticals Business Overview
  34. 8.6.3 Enanta Pharmaceuticals Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Enanta Pharmaceuticals Drugs for Vancomycin-Resistant Enterococcus Faecium Product Portfolio
  36. 8.6.5 Enanta Pharmaceuticals Recent Developments
  37. 8.7 Cellceutix Corporation
  38. 8.7.1 Cellceutix Corporation Company Information
  39. 8.7.2 Cellceutix Corporation Business Overview
  40. 8.7.3 Cellceutix Corporation Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Cellceutix Corporation Drugs for Vancomycin-Resistant Enterococcus Faecium Product Portfolio
  42. 8.7.5 Cellceutix Corporation Recent Developments
  43. 8.8 Aphios Corporation
  44. 8.8.1 Aphios Corporation Company Information
  45. 8.8.2 Aphios Corporation Business Overview
  46. 8.8.3 Aphios Corporation Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Aphios Corporation Drugs for Vancomycin-Resistant Enterococcus Faecium Product Portfolio
  48. 8.8.5 Aphios Corporation Recent Developments
  49. 8.9 Alvogen
  50. 8.9.1 Alvogen Company Information
  51. 8.9.2 Alvogen Business Overview
  52. 8.9.3 Alvogen Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Alvogen Drugs for Vancomycin-Resistant Enterococcus Faecium Product Portfolio
  54. 8.9.5 Alvogen Recent Developments
  55. 8.10 Alchemia Limited
  56. 8.10.1 Alchemia Limited Company Information
  57. 8.10.2 Alchemia Limited Business Overview
  58. 8.10.3 Alchemia Limited Drugs for Vancomycin-Resistant Enterococcus Faecium Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Alchemia Limited Drugs for Vancomycin-Resistant Enterococcus Faecium Product Portfolio
  60. 8.10.5 Alchemia Limited Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst